AC Immune S.A.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACIU research report →
Companywww.acimmune.com
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD).
- CEO
- Andrea Pfeifer
- IPO
- 2016
- Employees
- 133
- HQ
- Lausanne, CH
Price Chart
Valuation
- Market Cap
- $294.13M
- P/E
- -3.39
- P/S
- 62.52
- P/B
- 7.12
- EV/EBITDA
- -3.36
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -1749.00%
- Net Margin
- -1788.79%
- ROE
- -123.98%
- ROIC
- -140.76%
Growth & Income
- Revenue
- $3.57M · -86.92%
- Net Income
- $-70,447,000 · -38.36%
- EPS
- $-0.70 · -37.25%
- Op Income
- $-68,863,000
- FCF YoY
- -202.67%
Performance & Tape
- 52W High
- $4.00
- 52W Low
- $1.60
- 50D MA
- $2.96
- 200D MA
- $2.94
- Beta
- 1.65
- Avg Volume
- 280.41K
Get TickerSpark's AI analysis on ACIU
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Start Free Trial →Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 15, 26 | Pfeifer Andrea | sell | 10,000 |
| Apr 15, 26 | Pfeifer Andrea | sell | 10,000 |
| Apr 15, 26 | Pfeifer Andrea | buy | 10,000 |
| Mar 18, 26 | Zuegel Martin | other | 0 |
| Mar 18, 26 | Zuegel Martin | other | 32,061 |
| Mar 20, 26 | Donati Piergiorgio | other | 0 |
| Mar 20, 26 | Donati Piergiorgio | other | 7,200 |
| Mar 20, 26 | Donati Piergiorgio | other | 41,322 |
| Mar 20, 26 | Donati Piergiorgio | other | 34,562 |
| Mar 20, 26 | Donati Piergiorgio | other | 28,463 |
Our ACIU Coverage
We haven't published any research on ACIU yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ACIU Report →